Captive cell therapy test based on Bob Langer research is still terminated, the latest results will be issued next month

In July this year, Flagship Pioneering (FP) hatched package cell therapy Xinrui Sigilon Therapeutics Inc. (NASDAQ: SGTX) received the US FDA notification, suspended its patients with moderate or severe hemophilia for moderate or severe hemophilia Clinical trials of I / II.

The discontinuation of this test was due to a "a common treatment complication" in a patient. Prior to this, SIGILON has submitted a serious adverse event (SAE) report to the FDA and other regulators and suspend registration processes.

SIGILON launched in 2017 Robert Langer and Daniel Anderson laboratory in MIT. It is reported that SIGILON is listed in Nasdaque in December last year, and the market value is once more than 1 billion US dollars. At present, the company’s market value is only $ 122 million. And after the price of $ 18 in 18 US dollars, SIGILON is only slightly above $ 3.5 after the price of $ 48.

Robert Langer and MIT Daniel Anderson Laboratory research results based on Moderna Important Behind: SIGILON established the SIGILDED LIVING Therapeutics? (SLTX) technology platform, the engineering cell package is implanted into the patient. Its technical purpose is to protect the influence of the cells from the human immune system and prevent side effects. Therefore, some investors expressed concern for the test caused by complications due to complications.

Recently, SIGILON announced that after a patient in clinical study of only three people reported a serious adverse incident, the patient received laparoscopic surgery specified by the researcher to remove the implanted sphere. After inspection, it was determined that the sphere placed in the patient was already fibrilized, and the cells in the sphere no longer have vitality.

The patient accepted the highest dose in three individuals receiving the treatment, and there was a factor VIII antibody after the spherical implantation, which may be the cause of the patient to face uncontrolled bleeding risks.

Although the company surveyed the patient’s fibrotic sphere, all three patients participating in the SIG-001 test will continue to follow up in accordance with the research agreement. These findings may have an impact on the time of Patients in the I / II clinical trial of the SIG-005 I-type Polycharant Storage (MPS-1).

"Guaranteed patient safety is our primary task, we are collecting information to understand these observations," said Dr. Rogerio Vivaldi, President and CEO of Sigilon, "We will work closely with FDA, other regulators and company consultants to determine these Observation results on our project. "

Figure | Color scanning electron micrograph of blood clots (Source: The New York Times)

Hemophilia is a hereditary disease due to the lack of certain coagulation factors in the blood. The main manifestation of this disease is that it is difficult for blood and blood, and traditional therapy is long-term infusion condensation factor VIII.

Sigilon developed SIG-001 Hemophilia Type Tytopathic, by encapsulating cells that produce coagulation factor VIII into a semi-permeable protective film and implanted into a patient, while producing Caggered Factor VIII (FVIII) Free from an immune system attack and prevent scar tissue around it.

The SIGILON product line is mainly for three types of disease treatment: rare blood disease, lysosome disease and endocrine and other chronic diseases. It is to be explained that SIG-001 is the only major candidate drug that the company enters the clinical stage. If the test cannot be recovered, then SIGILON’s main push line will become two lysosomes that are currently undergoing clinical test. therapy.

Figure SIGILON R & D line (Source: SIGILON)

It is still unclear whether treatment has led to this adverse reaction incident, and the company spokesperson Brandon Hagen refused to express comments after the press release. SIGILON said in its published message, the results will be reviewed and evaluated in the SIG-001 Security Review Committee on next month.

Reference:

-End-

Bihui "The Innovative Application of Life Science Qihai Tracking Biotechnology" series audio program officially launched, we will take you to explore more interesting life science industry!

Open source big face: InsightFace takes you to create a face recognition system for unpacking

Guide

Referring to the open source technology of artificial intelligence and face recognition, I believe that many peers in the industry should be unfamiliar with InsightFace, which is quoted more than 2100+, since 2018 Open Source, also maintains a strong growth situation in GitHub .

It can also be seen on the actual effect map displayed in the project.

And in the past year, InsightFace continues to maintain strong and active updates:

Among them, there is a large number of new progress in academic circles, international competitions (ICCV21, NIST-FRVT), and also supports a variety of frameworks (MXNET, Pytorch, PaddlePaddle).

1 InsightFace Framework

Insightface is an open source 2D & 3D deep face analysis toolbox, which highly enables rich and diverse face recognition, face detection and face algorithm, and optimized for training and deployment, assessing, competition in multiple algorithms. Get a winning.

2 Added support based on PaddlePaddle framework implementing a face recognition system

Based on the arser-based Blazeface, ArcFace and MobileFace, unpacking and a certain speed advantage, support large-scale distributed training, high throughput, and support 60 million categories.

(1) ARCFACE model is open and has a certain speed advantage

  • Use the box

  • Speed ??advantage

(2) The RESNET large-scale distributed training rate is high, up to 60 million categories

  • Throughout the lead

  • Maximum support for 60 million categories

(3) a line of code practice simple face recognition Demo

Example scripts for detecting + identifying series predictions are as follows:

Python3.7 Tools / Test_Recognition.py – Det – Rec –index=index.bin –input=Friends2.jpg –output="http://www.yidianzixun.com/article/output"

The final visual results are stored in the Output directory, and the visual results are shown below.

Portal:

3 Welfare time

In order to make everyone more familiar with Insightface, understand the latest update progress, the InsightFac initiates people with the average developers, live in the B station, and share the latest progress for everyone.

4 Registration course joining technology exchange group

GitHub: https://github.com/deepinsight/insightface

Watch: Bangladesh fans taunt Shaheen Afridi with ‘Matthew Wade’ chants, PAK pacer responds with fifer

Pakistan pacer Shaheen Shah Afridi responded to ‘Mathew Wade’ taunts from the Bangladesh fans by taking a five-wicket haul wicket on the fourth day of the First Test played at Chattogram.

The incident took place on Day 3 of the ongoing Test when Afridi dived to save a boundary, a section of the crowd reminded him of Wade’s hat-trick of sixes, which was caught on the mic.

The left-arm quick from Pakistan was taken to the cleaners by Australia’s Matthew Wade during their T20 World Cup semi-final clash, earlier this month.

Shaheen ended up having the last laugh over as he made full use of new ball and dismissed Shadman Islam and Najmul Shanto in the space of three deliveries. The Pakistan quick later added the wicket of Saif Hassan with a caught and bowled off a meanly directed bouncer. On Day 4, he added two more wickets in his kitty to complete his fourth five-wicket haul in Test cricket.

The 21-year-old returned with an impressive bowling figure of 5/32 in Bangladesh’s second innings and restricted the hosts to 157.

Afridi, playing in his 20th Test match has a stellar record in the game longer format. The young speedster has bagged 86 wickets in 20 matches for Pakistan.

Yasir hurt, Bangladesh extends lead to 200 over Pakistan

Yasir Ali had to be replaced by a concussion substitute after after being hit on the helmet before Bangladesh was bowled out for 157 after the lunch on day four.

Liton Das, who scored 114 in the first innings, scored a feisty 59 after combining with Yasir in a 47-run stand.

For Pakistan, Shaheen Shah Afridi (5/32), Sajid Khan (3/32) and Hasan Ali (2/52) shared the spoils.

Pakistan needs 201 runs to go 1-0 up in the two-match Test series.